| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
880 |
790 |
$79K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
163 |
149 |
$15K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
108 |
106 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
235 |
199 |
$12K |
| 92552 |
|
250 |
243 |
$6K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
310 |
298 |
$6K |
| 99385 |
|
45 |
43 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
48 |
42 |
$5K |
| 94760 |
|
1,227 |
1,077 |
$3K |
| 0240U |
|
17 |
17 |
$2K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
14 |
14 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
16 |
16 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
16 |
$821.28 |
| 36415 |
Collection of venous blood by venipuncture |
291 |
271 |
$618.27 |
| 99173 |
|
238 |
225 |
$569.40 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
39 |
28 |
$540.99 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
39 |
28 |
$540.99 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
15 |
15 |
$491.23 |
| 96160 |
|
161 |
153 |
$415.49 |
| 90661 |
|
13 |
12 |
$243.60 |
| 96127 |
|
42 |
40 |
$235.50 |